Search research articles
Contact Us
Filters
Showing results (31-40 of 44) with videos related to
Page
of 5
Sort By:
The Journal of General Virology
|
October 1, 1995
Proteolytic cleavage of VP2, an outer capsid protein of African horse sickness virus, by species-specific serum proteases enhances infectivity in Culicoides
P R Marchi, P Rawlings, J N Burroughs, et al.
Cell
|
May 25, 1999
The highly ordered double-stranded RNA genome of bluetongue virus revealed by crystallography
P Gouet, J M Diprose, J M Grimes, et al.
Journal of Virological Methods
|
September 3, 2003
A group-specific, indirect sandwich ELISA for the detection of equine encephalosis virus antigen
J E Crafford, A J Guthrie, M van Vuuren, et al.
Nature
|
October 17, 1998
The atomic structure of the bluetongue virus core
J M Grimes, J N Burroughs, P Gouet, et al.
Virology
|
March 15, 1996
Enhanced infectivity of modified bluetongue virus particles for two insect cell lines and for two Culicoides vector species
P P Mertens, J N Burroughs, A Walton, et al.
Virology
|
June 1, 1989
Analysis of the roles of bluetongue virus outer capsid proteins VP2 and VP5 in determination of virus serotype
P P Mertens, S Pedley, J Cowley, et al.
Journal of Virology
|
August 21, 2002
The core of bluetongue virus binds double-stranded RNA
J M Diprose, J M Grimes, G C Sutton, et al.
Journal of Virological Methods
|
April 5, 2011
A competitive ELISA for the detection of group-specific antibody to equine encephalosis virus
J E Crafford, A J Guthrie, M Van Vuuren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1992
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer
D I Jodrell, M J Egorin, R M Canetta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 1993
Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer
L M Reyno, M J Egorin, R M Canetta, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 44) with videos related to
Sort By:
Page
of 5
The Journal of General Virology
|
October 1, 1995
Proteolytic cleavage of VP2, an outer capsid protein of African horse sickness virus, by species-specific serum proteases enhances infectivity in Culicoides
P R Marchi, P Rawlings, J N Burroughs, et al.
Cell
|
May 25, 1999
The highly ordered double-stranded RNA genome of bluetongue virus revealed by crystallography
P Gouet, J M Diprose, J M Grimes, et al.
Journal of Virological Methods
|
September 3, 2003
A group-specific, indirect sandwich ELISA for the detection of equine encephalosis virus antigen
J E Crafford, A J Guthrie, M van Vuuren, et al.
Nature
|
October 17, 1998
The atomic structure of the bluetongue virus core
J M Grimes, J N Burroughs, P Gouet, et al.
Virology
|
March 15, 1996
Enhanced infectivity of modified bluetongue virus particles for two insect cell lines and for two Culicoides vector species
P P Mertens, J N Burroughs, A Walton, et al.
Virology
|
June 1, 1989
Analysis of the roles of bluetongue virus outer capsid proteins VP2 and VP5 in determination of virus serotype
P P Mertens, S Pedley, J Cowley, et al.
Journal of Virology
|
August 21, 2002
The core of bluetongue virus binds double-stranded RNA
J M Diprose, J M Grimes, G C Sutton, et al.
Journal of Virological Methods
|
April 5, 2011
A competitive ELISA for the detection of group-specific antibody to equine encephalosis virus
J E Crafford, A J Guthrie, M Van Vuuren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1992
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer
D I Jodrell, M J Egorin, R M Canetta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 1993
Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer
L M Reyno, M J Egorin, R M Canetta, et al.
Page
of 5